-
21.发明申请公开(公告)号：US20190331694A1
公开(公告)日：2019-10-31
申请号：US16422256
申请日：2019-05-24
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Mader , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
-
公开(公告)号：US10100129B2
公开(公告)日：2018-10-16
申请号：US15520638
申请日：2015-11-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: A61K39/00 , C07K16/40 , C07K16/28 , A61K47/68 , C07K16/30 , A61K39/395 , A61K45/06 , G01N33/574
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.
-
公开(公告)号：US09840562B2
公开(公告)日：2017-12-12
申请号：US14692948
申请日：2015-04-22
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Jing Min , Yanli Wu , Rory F. Finn , Barrett R. Thiele , Wei Liao , Ronald P. Gladue , Arvind Rajpal , Timothy J. Paradis , Peter Brams , Brigitte Devaux , Yi Wu , Kristopher Toy , Heidi N. LeBlanc , Haichun Huang
CPC classification number: C07K16/2878 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/565 , C07K2317/92
Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
-
24.发明申请TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF 有权肿瘤坏死因子类似配体1A特异性抗体及其组合物及其用途公开(公告)号：US20150132311A1
公开(公告)日：2015-05-14
申请号：US14539845
申请日：2014-11-12
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Madar , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
CPC classification number: G01N33/6863 , C07K16/2875 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
Abstract translation: 本发明提供特异性结合TL1A的抗体或其抗原结合片段。 本发明还提供了获得这样的抗体的方法和编码该抗体的核酸。 本发明还涉及使用这些抗体治疗和/或预防TL1A介导的疾病，病症或病症的组合物和治疗方法。
-
25.发明授权公开(公告)号：US11474112B2
公开(公告)日：2022-10-18
申请号：US16422256
申请日：2019-05-24
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Mader , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand 1A(TL1A) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
-
Patent Agency Ranking
公开(公告)号：US11352440B2
公开(公告)日：2022-06-07
申请号：US16117183
申请日：2018-08-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: A61K39/395 , C07K16/40 , C07K16/28 , C07K16/30 , G01N33/573 , A61K47/68 , A61K45/06 , G01N33/574 , A61K39/00
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US10167343B2
公开(公告)日：2019-01-01
申请号：US15432180
申请日：2017-02-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/30 , C07K16/40 , A61K39/00 , A61K39/395 , A61K45/06 , G01N33/573 , C07K16/28
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
28.发明授权公开(公告)号：US09683998B2
公开(公告)日：2017-06-20
申请号：US14539845
申请日：2014-11-12
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Madar , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
CPC classification number: G01N33/6863 , C07K16/2875 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor-like ligand 1A (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
-
公开(公告)号：US09605080B2
公开(公告)日：2017-03-28
申请号：US14994828
申请日：2016-01-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/30 , C07K16/40 , A61K39/00 , A61K39/395 , A61K45/06 , G01N33/573
CPC classification number: C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/573 , G01N2333/916
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US20140127229A1
公开(公告)日：2014-05-08
申请号：US14055238
申请日：2013-10-16
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Allison Y. Luo , Wendy L. Trigona , Jinshan Shen , Li-An Xu , Yan Zhang , Bruce Stouffer , Haibin Chen , Haichun Huang , Xiaolu Tao , Catherine Brockus
IPC: G01N33/68
CPC classification number: G01N33/686 , A61K39/3955 , A61K2039/505 , C07K16/24 , C07K16/4208 , C07K2317/21 , C07K2317/76 , C07K2317/90
Abstract: In certain embodiments, the present invention provides a method of treating an IP-10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IP-10 antibody; (b) detecting the level of the anti-IP-10 antibody in a sample of the subject; and (c) if the level of the anti-IP-10 antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IP-10 antibody in the subject such that the IP-10 related disease in the subject is treated. In certain embodiments, the present invention provides an isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-IP-10 antibody MDX-1100.
Abstract translation: 在某些实施方案中，本发明提供了治疗受试者中IP-10相关疾病的方法，包括：（a）向受试者施用预定剂量的抗-IP-10抗体; （b）检测受试者样品中抗-IP-10抗体的水平; 和（c）如果来自步骤（b）的抗-IP-10抗体的水平低于临界暴露水平，则增加受试者中抗-IP-10抗体的剂量使得IP-10相关疾病在 该主题得到对待。 在某些实施方案中，本发明提供了与抗-IP-10抗体MDX-1100结合的分离的单克隆抗独特型抗体或其抗原结合部分。
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.051 seconds)
